Low-intensity focused ultrasound (FUS) is a noninvasive neuromodulation method capable of reaching deep brain structures with millimeter-scale precision. The authors frame the amygdala as a central node in affective neurocircuitry and a logical target for psychiatric intervention in disorders such as major depressive disorder and anxiety. This report describes a first-in-human, active-controlled trial that evaluated safety and evidence of target engagement for amygdala-targeted FUS.
The study was a single-blind randomized crossover trial (ClinicalTrials.gov NCT05147142) enrolling ten participants with major depressive disorder. Each participant underwent two sonication sessions in randomized order: one targeting the right amygdala and one targeting the left primary somatosensory cortex, the latter serving as an active control. Blinded symptom raters evaluated clinical outcomes. Nine participants completed both sessions; details on dropouts and individual-level demographics are provided in the manuscript.
Each sonication session consisted of two 10-minute applications delivered within diagnostic ultrasound safety limits. Sonication was image-guided to target the predefined brain region (right amygdala or left primary somatosensory cortex). The device and parameters were operated under an Investigational Device Exemption (IDE G200146) as required by the US Food and Drug Administration.
Primary outcomes focused on safety and objective measures of target engagement. Safety was assessed with neurological and neuropsychological examinations and MRI safety checks. Target engagement was evaluated multimodally: BOLD fMRI acquired during sonication, post-sonication arterial spin labeling (ASL) perfusion imaging, and resting-state functional connectivity analyses. These imaging endpoints were selected to detect local physiological effects at the targeted amygdala and downstream circuit-level changes.
Post-sonication ASL demonstrated greater perfusion change in the targeted amygdala after amygdala sonication compared to the control-targeted region (p < 0.001). A similar perfusion increase was observed in the ipsilateral hippocampus (p < 0.001), indicating anatomically specific effects extending to adjacent medial temporal structures.
BOLD fMRI recorded during sonication revealed engagement of medial prefrontal-limbic circuitry, specifically the ventromedial prefrontal cortex and rostral anterior cingulate regions. These activations indicate acute modulation of prefrontal regions connected with the amygdala during sonication.
In post-sonication resting-state analyses, connectivity between the basolateral amygdala and sensorimotor regions decreased; these connectivity changes survived correction for multiple comparisons (corrected p values < 0.05). Together, the perfusion, BOLD, and connectivity results provide convergent, anatomically specific evidence of neuromodulation at both the target and circuit level.
At the group level, symptom improvement did not differ significantly between the amygdala-targeted and control sonication conditions. Exploratory analyses investigating relationships between imaging changes and symptom measures did yield significant imaging–symptom associations, which the authors report as hypothesis-generating.
Notably, spontaneous subjective reports of acute experiences—described as calm, clarity, or lightness—occurred following amygdala sonication but not after control sonication (p < 0.001). These subjective effects were observed despite the lack of a group-level differential symptom effect in blinded ratings.
No serious adverse events were reported. Standard neurological, neuropsychological, and MRI safety assessments were unremarkable across participants. However, adverse events were statistically more frequent after amygdala sonication compared with control (p = 0.028). One participant experienced clinical worsening following amygdala sonication and required monitoring. The authors characterize the overall safety profile as manageable but note the need for continued caution and surveillance in future trials.
The trial was approved by the VA Providence Institutional Review Board and conducted under FDA IDE G200146. The manuscript states that all necessary participant consent and ethical approvals were obtained. Funding sources listed include the National Institute of Mental Health, the US Department of Veterans Affairs, the Brain & Behavior Research Foundation, and the Focused Ultrasound Foundation. Several authors reported financial relationships or consulting roles with commercial entities; these disclosures are detailed in the source manuscript.
In this first-in-human active-controlled trial, amygdala-targeted low-intensity focused ultrasound produced anatomically specific, multimodal imaging evidence of neuromodulation relative to an active cortical control while maintaining a generally manageable safety profile. Imaging signals included focal perfusion increases, engagement of ventromedial prefrontal and rostral anterior cingulate regions during sonication, and reduced basolateral amygdala–sensorimotor resting connectivity after sonication. Group-level symptom change did not differ between conditions, though exploratory imaging–symptom relationships and subjective reports of calm or clarity after amygdala sonication were observed. The authors conclude that convergent target- and circuit-level effects support further development of FUS as a precision approach for modulating deep brain targets in psychiatric disorders.